$429 Million is the total value of Samsara BioCapital, LLC's 56 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 14.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FMTX | Sell | FORMA THERAPEUTICS HLDGS INC | $21,255,000 | +97.1% | 1,065,413 | -31.9% | 4.96% | +72.4% |
| ISEE | Sell | IVERIC BIO INC | $14,496,000 | +49.2% | 808,041 | -20.0% | 3.38% | +30.5% |
| Sell | HILLEVAX INC | $10,426,000 | +25.1% | 610,062 | -20.0% | 2.43% | +9.4% | |
| VRNA | Sell | VERONA PHARMA PLCsponsored ads | $9,595,000 | +106.1% | 938,890 | -15.5% | 2.24% | +80.3% |
| SYRS | Sell | SYROS PHARMACEUTICALS INC | $5,677,000 | +210.4% | 881,450 | -53.6% | 1.32% | +171.3% |
| IMCR | Sell | IMMUNOCORE HLDGS PLCads | $3,800,000 | -36.7% | 80,963 | -49.7% | 0.89% | -44.7% |
| RXRX | Exit | RECURSION PHARMACEUTICALS INcl a | $0 | – | -267,996 | -100.0% | -0.58% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Intercept Pharmaceuticals Inc | 20 | Q3 2023 | 24.0% |
| ALLAKOS INC | 20 | Q3 2023 | 23.0% |
| SUTRO BIOPHARMA INC | 20 | Q3 2023 | 10.1% |
| SYROS PHARMACEUTICALS INC | 16 | Q3 2022 | 11.6% |
| ATRECA INC | 16 | Q1 2023 | 7.4% |
| IVERIC BIO INC | 15 | Q2 2023 | 5.5% |
| ACLARIS THERAPEUTICS INC | 15 | Q3 2023 | 4.8% |
| RHYTHM PHARMACEUTICALS INC | 15 | Q3 2023 | 2.4% |
| ODONATE THERAPEUTICS INC | 14 | Q1 2022 | 14.9% |
| SPRINGWORKS THERAPEUTICS INC | 14 | Q4 2022 | 12.1% |
View Samsara BioCapital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Samsara BioCapital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.